Insights & Research

The distinction between prophylactic and therapeutic dosing in preclinical fibrosis models can determine clinical trial success. We discuss the appropriate dosing timelines across Bleomycin (IPF), GAN diet (MASH), and UUO (renal fibrosis) models, and the lessons from clinical failures of Simtuzumab and Selonsertib.

The Bleomycin pulmonary fibrosis model is the gold standard for IPF drug discovery. We explain solutions to its biggest challenges—"spontaneous resolution" and "variability"—using Micro-Sprayer technology for uniform administration and optimal study design.

There is no 'perfect MASH model.' We explain the importance of the 'Multi-Model Portfolio Strategy'—combining metabolic-focused (GAN) and fibrosis-focused (CDAHFD/CCl4) models—as seen in the development of Semaglutide.

Incorporating in-life liver biopsy into preclinical MASH studies enables paired (intra-individual) analysis, dramatically improving alignment with clinical trial design. We detail the surgical technique, statistical advantages, and AI-powered scoring of biopsy-confirmed study designs.

Prevent 'worked in animals, failed in clinic' in SSc drug development. Compare the 5 major models — Bleomycin, HOCl, Tsk, GVHD, and Fra-2 — from a clinical predictivity perspective, with a target-by-MoA selection guide.

'Skin hardened but lungs didn't improve.' 'Immunotherapy had no effect.' To avoid failures in SSc drug development, we provide a detailed comparison of dosing protocols and evaluation methods for Bleomycin, HOCl, Tsk, and Fra-2 models.

Exploring the dual role of exosomes as diagnostic biomarkers and therapeutic tools in fibrotic diseases.

Exploring the role of cardiac fibrosis in heart failure (HFpEF) and novel therapeutic approaches including SGLT2 inhibitors and GLP-1 receptor agonists.

Exploring how senescent cells drive fibrosis and how Senolytic drugs represent a revolutionary approach to treating IPF and MASH.

Exploring the latest developments in anti-fibrotic strategies targeting tissue-specific TGF-β activation via αvβ6/αvβ1 integrins.

Effective in MI models, failed in HFpEF trials. The reason? Wrong model. Learn how to select the right HFpEF model (TAC, AngII, Multi-hit) targeting diastolic dysfunction and fibrosis, with E/e' echocardiography and Azan staining correlation analysis.

For researchers facing 'no reproducibility' or 'unexpected negative data' in preclinical studies. We explain failure causes from mismatch of model selection and evaluation systems, and introduce 3 re-evaluation strategies: STAM model, AI pathology, and PRO-C3.

'It worked in mice, but not in humans.' The key to crossing this valley of death is to evaluate with the same 'measure' as clinical trials. We explain how to utilize non-invasive biomarkers like FibroScan (CAP/VCTE), PRO-C3, and ELF score.

Following the FDA Modernization Act 2.0, interest in Organ-on-a-Chip (MPS) is skyrocketing. We explore its potential to replace animal models in fibrosis research, its current limitations, and the pragmatic 'Hybrid Strategy'.

Discover the 2025 MASH/MASLD drug development landscape. A comprehensive analysis of GSK, Roche, and Novo Nordisk mega-deals, FGF21 analog pipelines, and interactive industry realignment maps for pharma professionals.

Analysis of the latest trends in the IPF field in 2025. Visualizing a year of contrasts with Boehringer Ingelheim's first new approval in over a decade, United Therapeutics' Phase 3 success, and Pliant's discontinuation.

Unsure if a quote is fair? Struggling to choose the right CRO? Discover the key cost drivers of preclinical fibrosis studies and a 3-point checklist to ensure high-quality data and successful outsourcing.

Improve the success rate of IBD drug discovery by correctly selecting between DSS and TNBS models. We explain the benefits of Pre-validated DSS and endoscopic evaluation (MEICS).

An in-depth guide to the forefront of MASH therapeutics, drastically shifting since the 2024 approval of Resmetirom. We compare Phase 2/3 clinical data with preclinical GAN DIO-MASH models, detailing the potential and correlative mechanisms of next-generation drugs like Semaglutide, Lanifibranor, and Efruxifermin, along with future prospects for Lean MASH.

A comprehensive analysis of the IPF drug development landscape in 2025. From pirfenidone and nintedanib to the newly approved nerandomilast and breakthrough Phase 2 candidates showing FVC improvement, we cover clinical data, mechanisms of action, and preclinical evidence.

Overcoming challenges in the Bleomycin IPF model. How Micro-Sprayer® technology and therapeutic dosing designs improve clinical predictability in preclinical trials.

Ofev/Esbriet only slow progression. Nerandomilast (Jascayd) showed add-on efficacy and won FDA approval in 2025. We decode the precision molecular design of PDE4B selectivity and the FIBRONEER-IPF data.

Resmetirom alone: 25% fibrosis improvement. Semaglutide: 37%. The majority DON'T improve. The answer? Combination therapy. We map out the optimal FGF21 + GLP-1 + THR-β combos for the Post-Monotherapy era.

Semaglutide's ESSENCE trial delivered 63% MASH resolution—but only 37% fibrosis improvement. Is 'Lose weight, cure liver' the whole truth? We explore the limits in Lean MASH and when to use Resmetirom instead.

Resmetirom was approved in 2024—the first MASH drug ever. But with ~25% fibrosis improvement, 75% of patients still need better options. What's the winning Post-Rezdiffra strategy? We decode the science of THR-β and MAESTRO-NASH.

The developmental program that builds fetal organs, when reactivated in adults, can trigger fibrosis. Why does 'Wnt reactivation' occur in mature tissue? We explore TGF-β crosstalk and the Wnt pathway's potential as a drug target.

Chronic inflammation causes fibrosis—that's known. But WHEN is the 'tipping point'? We decode M1→M2 macrophage polarization, TGF-β duality, and EMT to identify the optimal timing for therapeutic intervention.

Inflammation is not just a defense response but a crucial step towards tissue repair. We explain the initiation of acute inflammation, the active "resolution" via SPMs (Specialized Pro-resolving Mediators) and Efferocytosis, and the mechanisms of transition to chronicity.

Why do anti-fibrotic drugs keep failing? The answer lies in controlling the myofibroblast. We systematically explain TGF-β signaling, mechanotransduction, and the 'Achilles heel' for targeted drug discovery.

Myofibroblasts—the executors of fibrosis—should disappear after wound healing. Why do they persist and worsen fibrosis? We explore their origins (resident, pericyte, EMT) and survival signals to identify drug targets.

We explain the mechanisms of Pirfenidone and Nintedanib, approved for Idiopathic Pulmonary Fibrosis (IPF), and the latest development trends of novel anti-fibrotic candidates for MASH and renal fibrosis currently in Phase 2/3 clinical trials.

Biomarkers are essential for non-invasive evaluation of fibrosis. We explain the diagnostic value, prognostic ability, and limitations of major markers for lung (KL-6, SP-D), liver (Hyaluronic Acid, ELF Score), heart, and kidney.